ALLMedicine™ Ataxia Telangiectasia Center
Research & Reviews 677 results
https://clinicaltrials.gov/ct2/show/NCT04826341
May 20th, 2022 - Background: Several small molecule poly-(ADP)-ribose polymerase inhibitors (PARPi) have been approved by the FDA for multiple cancers with homologous recombination (HR) deficiencies. Despite their measurable initial benefit, PARPi resistance is a ...
https://doi.org/10.1016/j.brainresbull.2022.05.008
Brain Research Bulletin; Wang X, Wang Z et. al.
May 20th, 2022 - Subarachnoid hemorrhage (SAH), a type of hemorrhagic stroke, is a neurological emergency with high morbidity and mortality. Early brain injury (EBI) after SAH is the leading cause of poor prognosis in SAH patients. TRX system is a NADPH-dependent ...
https://clinicaltrials.gov/ct2/show/NCT00455325
May 10th, 2022 - Metabolic syndrome is one of the most common disorders in industrialized countries. It consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central obesity in the setting of insulin resistance. The syndrome substant...
https://doi.org/10.1007/s00280-022-04436-0 10.1016/j.molcel.2017.05.015 10.1038/s41568-018-0034-3 10.1016/j.radonc.2017.09.043 10.1016/j.ctrv.2013.03.002 10.1016/j.crphar.2021.100017 10.3390/ph3051311 10.1038/bjc.2017.376 10.1172/JCI96519 10.1158/2159-8290.CD-20-0868 10.1158/1535-7163.MCT-19-0019 10.1021/acs.jmedchem.0c00369 10.1007/BF01062139 10.1111/j.1365-2125.1981.tb01304.x 10.2165/00003088-198409010-00001 10.1016/j.steroids.2012.01.007 10.1016/s0169-409x(97)00039-2 10.1172/JCI34007 10.1007/s00280-021-04388-x 10.4155/tde.11.19 10.1002/jps.24505 10.1007/s00280-016-3181-9 10.1208/s12248-011-9290-9 10.1208/s12248-009-9098-z 10.1016/s0360-3016(99)00558-1 10.1023/A:1018943613122
Cancer Chemotherapy and Pharmacology; Kiesel BF, Deppas JJ et. al.
May 5th, 2022 - Ataxia Telangiectasia and Rad3-related (ATR) is a pivotal component of the DNA damage response and repair pathways that is activated in responses to cytotoxic cancer treatments. Several ATR inhibitors (ATRi) are in development that block the ATR m...
https://clinicaltrials.gov/ct2/show/NCT04216316
May 3rd, 2022 - PRIMARY OBJECTIVES: I. To determine the recommended phase 2 dose (RP2D) of carboplatin in combination with berzosertib (M6620, VX-970) and gemcitabine/pembrolizumab, in patients with squamous cell non-small cell lung cancer (Sq-NSCLC). (Lead-in Ph...
Drugs 1 results see all →
Clinicaltrials.gov 14 results
https://clinicaltrials.gov/ct2/show/NCT04826341
May 20th, 2022 - Background: Several small molecule poly-(ADP)-ribose polymerase inhibitors (PARPi) have been approved by the FDA for multiple cancers with homologous recombination (HR) deficiencies. Despite their measurable initial benefit, PARPi resistance is a ...
https://clinicaltrials.gov/ct2/show/NCT00455325
May 10th, 2022 - Metabolic syndrome is one of the most common disorders in industrialized countries. It consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central obesity in the setting of insulin resistance. The syndrome substant...
https://clinicaltrials.gov/ct2/show/NCT04216316
May 3rd, 2022 - PRIMARY OBJECTIVES: I. To determine the recommended phase 2 dose (RP2D) of carboplatin in combination with berzosertib (M6620, VX-970) and gemcitabine/pembrolizumab, in patients with squamous cell non-small cell lung cancer (Sq-NSCLC). (Lead-in Ph...
https://clinicaltrials.gov/ct2/show/NCT04149145
Jan 24th, 2022 - The primary, secondary, and exploratory objective are to assess the safety of the combination of M4344 and Niraparib in a phase 1 trial of patients with PARP resistant recurrent ovarian cancer; to determine the response rate and percentage of part...
https://clinicaltrials.gov/ct2/show/NCT05116254
Nov 10th, 2021 - Despite improvements in surgery and radiation for soft tissue sarcoma (STS) patients, local relapses remain an important event for these patients. Most STS subtypes are considered radioresistant. Investigations into radiosensitization mediated by ...
News 13 results
https://www.medscape.com/viewarticle/971864
Apr 8th, 2022 - SEATTLE — A novel therapy for ataxia telangiectasia that delivers dexamethasone sodium phosphate (DSP) through autologous red blood cells has shown promise in a phase 3 clinical trial. The disease is an autosomal recessive disorder caused by mutat...
https://www.medscape.com/viewarticle/949638
Apr 21st, 2021 - NEW YORK (Reuters Health) - Combining an ataxia telangiectasia and rad3-related (ATR) inhibitor with topoisomerase 1 (TOP1) yielded an objective response in more than a third of patients with small-cell lung cancer (SCLC) in a phase-2 proof-of-con...
https://www.onclive.com/view/the-parp-inhibitors-down-but-not-out
Dec 5th, 2020 - Two views of the protein structure of a PARP1 inhibitor complex. Poly(ADP-ribose) polymerase (PARP) inhibitors, particularly Sanofi’s iniparib and AstraZeneca’s olaparib, have elicited both great excitement and significant disappointment in equa...
https://www.onclive.com/view/atr-inhibitors-offer-new-line-of-attack-on-dna-repair-network
Dec 5th, 2020 - Cancer cells that manipulate the DNA damage response (DDR) to foster the genomic instability that underlies many of their hallmark processes become heavily reliant on intact pathways for their survival, creating a targetable Achilles heel that can...
https://www.onclive.com/view/integrating-parp-inhibitors-into-the-treatment-of-womens-cancers
Dec 5th, 2020 - Franco Muggia, MD PARP Inhibition in Ovarian Cancer PARP enzymes are involved in a number of DNA repair processes. Tumors with pathogenic BRCA mutations are associated with a deficiency in homologous recombination, a critical double-stranded DNA...
